AR and neoplasm: In the presence of DHEA, an FDA approved Bruton’s tyrosine kinase (BTK) and BMX inhibitor, zanubrutinib, effectively blocked androgen receptor–positive (AR-positive) xenograft tumor growth in castrated mice (4).